Cargando…

Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus

There is a critical need for safe treatment options to control inflammation in patients with systemic lupus erythematosus (SLE) since the inflammation contributes to morbidity and mortality in advanced disease. Endogenous neuroimmune mechanisms like the cholinergic anti-inflammatory pathway can be t...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales, Jessica Y., Young-Stubbs, Cassandra M., Shimoura, Caroline G., Kem, William R., Uteshev, Victor V., Mathis, Keisa W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076522/
https://www.ncbi.nlm.nih.gov/pubmed/33928103
http://dx.doi.org/10.3389/fmed.2021.642960
_version_ 1783684696302944256
author Morales, Jessica Y.
Young-Stubbs, Cassandra M.
Shimoura, Caroline G.
Kem, William R.
Uteshev, Victor V.
Mathis, Keisa W.
author_facet Morales, Jessica Y.
Young-Stubbs, Cassandra M.
Shimoura, Caroline G.
Kem, William R.
Uteshev, Victor V.
Mathis, Keisa W.
author_sort Morales, Jessica Y.
collection PubMed
description There is a critical need for safe treatment options to control inflammation in patients with systemic lupus erythematosus (SLE) since the inflammation contributes to morbidity and mortality in advanced disease. Endogenous neuroimmune mechanisms like the cholinergic anti-inflammatory pathway can be targeted to modulate inflammation, but the ability to manipulate such pathways and reduce inflammation and end organ damage has not been fully explored in SLE. Positive allosteric modulators (PAM) are pharmacological agents that inhibit desensitization of the nicotinic acetylcholine receptor (α7-nAChR), the main anti-inflammatory feature within the cholinergic anti-inflammatory pathway, and may augment α7-dependent cholinergic tone to generate therapeutic benefits in SLE. In the current study, we hypothesize that activating the cholinergic anti-inflammatory pathway at the level of the α7-nAChR with systemic administration of a partial agonist, GTS-21, and a PAM, PNU-120596, would reduce inflammation, eliminating the associated end organ damage in a mouse model of SLE with advanced disease. Further, we hypothesize that systemic α7 ligands will have central effects and improve behavioral deficits in SLE mice. Female control (NZW) and SLE mice (NZBWF1) were administered GTS-21 or PNU-120596 subcutaneously via minipumps for 2 weeks. We found that the increased plasma dsDNA autoantibodies, splenic and renal inflammation, renal injury and hypertension usually observed in SLE mice with advanced disease at 35 weeks of age were not altered by GTS-21 or PNU-120596. The anxiety-like behavior presented in SLE mice was also not improved by GTS-21 or PNU-120596. Although no significant beneficial effects of α7 ligands were observed in SLE mice at this advanced stage, we predict that targeting this receptor earlier in the pathogenesis of the disease may prove to be efficacious and should be addressed in future studies.
format Online
Article
Text
id pubmed-8076522
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80765222021-04-28 Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus Morales, Jessica Y. Young-Stubbs, Cassandra M. Shimoura, Caroline G. Kem, William R. Uteshev, Victor V. Mathis, Keisa W. Front Med (Lausanne) Medicine There is a critical need for safe treatment options to control inflammation in patients with systemic lupus erythematosus (SLE) since the inflammation contributes to morbidity and mortality in advanced disease. Endogenous neuroimmune mechanisms like the cholinergic anti-inflammatory pathway can be targeted to modulate inflammation, but the ability to manipulate such pathways and reduce inflammation and end organ damage has not been fully explored in SLE. Positive allosteric modulators (PAM) are pharmacological agents that inhibit desensitization of the nicotinic acetylcholine receptor (α7-nAChR), the main anti-inflammatory feature within the cholinergic anti-inflammatory pathway, and may augment α7-dependent cholinergic tone to generate therapeutic benefits in SLE. In the current study, we hypothesize that activating the cholinergic anti-inflammatory pathway at the level of the α7-nAChR with systemic administration of a partial agonist, GTS-21, and a PAM, PNU-120596, would reduce inflammation, eliminating the associated end organ damage in a mouse model of SLE with advanced disease. Further, we hypothesize that systemic α7 ligands will have central effects and improve behavioral deficits in SLE mice. Female control (NZW) and SLE mice (NZBWF1) were administered GTS-21 or PNU-120596 subcutaneously via minipumps for 2 weeks. We found that the increased plasma dsDNA autoantibodies, splenic and renal inflammation, renal injury and hypertension usually observed in SLE mice with advanced disease at 35 weeks of age were not altered by GTS-21 or PNU-120596. The anxiety-like behavior presented in SLE mice was also not improved by GTS-21 or PNU-120596. Although no significant beneficial effects of α7 ligands were observed in SLE mice at this advanced stage, we predict that targeting this receptor earlier in the pathogenesis of the disease may prove to be efficacious and should be addressed in future studies. Frontiers Media S.A. 2021-04-13 /pmc/articles/PMC8076522/ /pubmed/33928103 http://dx.doi.org/10.3389/fmed.2021.642960 Text en Copyright © 2021 Morales, Young-Stubbs, Shimoura, Kem, Uteshev and Mathis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Morales, Jessica Y.
Young-Stubbs, Cassandra M.
Shimoura, Caroline G.
Kem, William R.
Uteshev, Victor V.
Mathis, Keisa W.
Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus
title Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus
title_full Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus
title_fullStr Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus
title_full_unstemmed Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus
title_short Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus
title_sort systemic administration of α7-nicotinic acetylcholine receptor ligands does not improve renal injury or behavior in mice with advanced systemic lupus erythematosus
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076522/
https://www.ncbi.nlm.nih.gov/pubmed/33928103
http://dx.doi.org/10.3389/fmed.2021.642960
work_keys_str_mv AT moralesjessicay systemicadministrationofa7nicotinicacetylcholinereceptorligandsdoesnotimproverenalinjuryorbehaviorinmicewithadvancedsystemiclupuserythematosus
AT youngstubbscassandram systemicadministrationofa7nicotinicacetylcholinereceptorligandsdoesnotimproverenalinjuryorbehaviorinmicewithadvancedsystemiclupuserythematosus
AT shimouracarolineg systemicadministrationofa7nicotinicacetylcholinereceptorligandsdoesnotimproverenalinjuryorbehaviorinmicewithadvancedsystemiclupuserythematosus
AT kemwilliamr systemicadministrationofa7nicotinicacetylcholinereceptorligandsdoesnotimproverenalinjuryorbehaviorinmicewithadvancedsystemiclupuserythematosus
AT uteshevvictorv systemicadministrationofa7nicotinicacetylcholinereceptorligandsdoesnotimproverenalinjuryorbehaviorinmicewithadvancedsystemiclupuserythematosus
AT mathiskeisaw systemicadministrationofa7nicotinicacetylcholinereceptorligandsdoesnotimproverenalinjuryorbehaviorinmicewithadvancedsystemiclupuserythematosus